• 2024年
• 2023年
• 2022年
• 2021年
• 2020年
• 2019年
• 2018年
• 2017年
• 2016年
• 2015年
• 2014年
• 2013年
• 2012年
• 2011年
• 2010年
• 2009年
• 2008年
• 2007年

研究業績 2023年

• Inoue C, Yamamoto T, Miyata H, Suzuki H, Takada T. Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients received allogeneic hematopoietic stem cell transplantation. J Pharm Health Care Sci. 2023 9(1):38. [open access]
• Ohno Y, Oriyama T, Honda A, Kurokawa M, Takada T. Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration. J Pharm Health Care Sci. 2023 9(1):39. [open access]
• Nakayama A, Kurajoh M, Toyoda Y, Takada T, Ichida K, Matsuo H. Dysuricemia. Biomedicines 2023 11(12):3169. [open access]
• Kiyomiya K, Tomabechi R, Saito N, Watai K, Takada T, Shirasaka Y, Kishimoto H, Higuchi K, Inoue K. Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug-ADC Interaction in Cancer Chemotherapy. Mol Pharm 2023 in press. [open access]
• Kuwabara M, Fukuuchi T, Aoki Y, Mizuta E, Ouchi M, Kurajoh M, Maruhashi T, Tanaka A, Morikawa N, Nishimiya K, Akashi N, Tanaka Y, Otani N, Morita M, Miyata H, Takada T, Tsutani H, Ogino K, Ichida K, Hisatome I, Abe K. Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. Biomolecules 2023 13(10):1519. [open access]
• Nara K, Yamamoto T, Yamashita H, Yagi K, Takada T, Seto Y, Suzuki H. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study. BMC Cancer 2023 23(1):979. [open access]
• Toyoda Y, Miyata H, Shigesawa R, Natsuo H, Suzuki H, Takada T. SVCT2/SLC23A2 is a sodium-dependent urate transporter: functional properties and practical application. J Biol Chem. 2023 299(8):104976. [open access]
• Nara K, Taguchi A, Yamamoto T, Hara K, Tojima Y, Honjoh H, Nishijima A, Eguchi S, Miyamoto Y, Sone K, Mori M, Takada T, Osuga Y. Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer. Int J Clin Oncol. 2023 28(9):1207-1217. [abstract]
• Sato H, Marutani R, Takaoka R, Mori-Fegan D, Wang X, Maeda K, Kusuhara H, SuzukiH, Yoshioka H, Hisaka A. Model-based meta-analysis of ethnic differences and their variabilities in clearance of oral drugs classified by clearance mechanism. CPT Pharmacometrics Syst Pharmacol. 2023 12(8):1132-1142. [open access]
• Nara K, Taguchi A, Yamamoto T, Tsuruga T, Tojima Y, Miyamoto Y, Tanikawa M, Sone K, Mori M, Takada T, Suzuki H, Osuga Y. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin. Support Care Cancer 2023 31(5):283. [open access]
• Yamaguchi R, Yamamoto T, Okamoto K, Harada S, Echizenya M, Tsutsumi T, Takada T. Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study. J Antimicrob Chemother. 2023 dkad079. [abstract]
• Matsuo M, Ogata Y, Yamanashi Y, Takada T. ABCG5 and ABCG8 Are Involved in Vitamin K Transport. Nutrients 2023 15(4):998. [abstract]
• Toyoda Y, Miyata H, Uchida N, Morimoto K, Shigesawa R, Kassai H, Nakao K, Tomioka HN, Matsuo H, Ichida K, Hosoyamada M, Aiba A, Suzuki H, Takada T. Vitamin C transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo investigations. Pflugers Arch. 2023 475(4):489-504. [open access]
• Nara K, Yamamoto T, Sato Y, Yagi K, Kawasaki K, Toriumi T, Takada T, Seto Y, Suzuki H. Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. Support Care Cancer 2023 31(2):150. [open access]
• Toyoda Y, Cho SK, Tasic V, Pavelcová K, Bohatá J, Suzuki H, David VA, Yoon J, Pallaiova A, Šaligová J, Nousome D, Cachau R, Winkler CA, Takada T, Stiburkova B. Identification of a dysfunctional exon-skipping splice variant in GLUT9/SLC2A9 causal for renal hypouricemia type 2. Front Genet. 2023 13:1048330. [open access]
• Ohashi Y, Kuriyama S, Nakano T, Sekine M, Toyoda Y, Nakayama A, Takada T, Kawamura Y, Nakamura T, Matsuo H, Yokoo T, Ichida K. Urate Transporter ABCG2 Function and Asymptomatic Hyperuricemia: A Retrospective Cohort Study of CKD Progression. Am J Kidney Dis. 2023 81(2):134-144.e1. [abstract]
• Tomabechi R, Miyasato M, Sato T, Takada T, Higuchi K, Kishimoto H, Shirasaka Y, Inoue K. Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3. Mol Pharm. 2023 20(1):491-499. [abstract]
• Honma M, Suzuki H. Can molecular dynamics facilitate the design of protein-protein-interaction inhibitors? Nat Rev Rheumatol. 2023 19:8-9. [abstract]